Dominik Thor

Dr. Dominik Thor


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Dominik ThorDominik Thor
Dominik Thor
APAndrea Pagani
Andrea Pagani
JBJulia Bukowiecki
Julia Bukowiecki
KHKhosrow S. Houschyar
Khosrow S. Houschyar
SKStig-Frederik T. Kølle
Stig-Frederik T. Kølle
DDDominik Duscher
Dominik Duscher
Androgenic alopecia (AGA) is a genetically predetermined condition that occurs as a result of stepwise miniaturization of the dermal papilla. During this process, the hair follicle suffers from increasing malnutrition and eventually dies, causing progressive hair loss. We recently highlighted that HIF-1α modulation may counteract hair loss. Here, we aim to demonstrate the positive influence of Tomorrowlabs HIF strengthening factor [HSF] hair restoration technology on hair biology in a monocentric blinded clinical trial over a total period of 9 months. A trial with 20 subjects (4 female and 16 male) and once-daily application of [HSF] hair restoration technology to the scalp was conducted. To assess the tolerability and efficacy of [HSF], testing included dermatological assessment, determination of hair loss by counting after combing, macro images of the head and TrichoScan evaluation of hair density as well as the proportion of anagen hair versus telogen hair. The clinical data show Tomorrowlabs [HSF] hair restoration to be safe and effective to counteract AGA. The use of Tomorrowlabs [HSF] hair restoration resulted in improvements in the clinical parameters of hair quality such as thickness (+7.2%), hair density (+14.3%) and shine and elasticity (+20.3%) during the test period. The effectiveness of the test product was further determined by a significant reduction in hair loss of an average of 66.8% in treatment-responsive subjects after 6 months and an increase in hair growth reaching up to 32.5%, with an average percentage change of 8.4% in all participants and 10.8% in the responsive patients (85% of the study cohort) after 9 months on TrichoScan evaluation. The hair growth cycle was harmonized with the result of an average anagen hair percentage increase of +8.0% and telogen hair percentage reduction of −14.0% shown in the test area. Applicable for both sexes in an alcohol-free formulation, beneficial to scalp health and free of complications or side effects, this novel product provides objectively measurable results counteracting hair loss paired with an improved look and feel of the hair.

21 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
APAndrea Pagani
Andrea Pagani
Dominik ThorDominik Thor
Dominik Thor
Adriana C PanayiAdriana C Panayi
Adriana C Panayi
Silvan Maximilian KleinSilvan Maximilian Klein
Silvan Maximilian Klein
SGSebastian Geis
Sebastian Geis
Dominik DuscherDominik Duscher
Dominik Duscher
Autoimmune-induced alopecia, such as alopecia areata, involves immune-mediated damage to hair follicles, leading to significant hair loss. Emerging therapies that stabilize hypoxia-inducible factor 1-alpha (HIF-1α) show promise in counteracting follicular degradation and supporting hair regrowth. This communication highlights the potential of iron chelators, specifically deferoxamine (DFO) and deferiprone (DFP), to stabilize HIF-1α by reducing iron availability, thereby promoting vascularization, cellular proliferation, and a regenerative environment in the hair follicle niche. Clinical trials with iron chelators demonstrated improvements in hair density, thickness, and elasticity, as well as a reduction in hair loss by up to 66.8% over six months. These findings underscore the therapeutic potential of iron chelators in autoimmune alopecia management. Future research should explore the synergistic use of iron chelators with immune-modulating therapies, positioning them as viable options in the evolving field of alopecia treatment.

22 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SISorina Ispas
Sorina Ispas
SMSanja Medenica
Sanja Medenica
LTLiliana Ana Tuta
Liliana Ana Tuta
AGAmit Gupta
Amit Gupta
MANFREDI RIZZOMANFREDI RIZZO
MANFREDI RIZZO
Dominik ThorDominik Thor
Dominik Thor
Cellular stress is not inherently detrimental; its biological consequences depend on intensity, duration, context, and the capacity for recovery. This narrative review proposes the Burn-ON/Burn-OUT paradigm as a hypothesis-generating framework describing the transition from adaptive cellular activation to progressive loss of cellular resilience. A structured literature search was conducted for English-language articles published between 2021 and 2026 in PubMed, Web of Science, and Scopus, focusing on cellular stress adaptation, mitochondrial dysfunction, integrated stress response, autophagy and mitophagy, redox signaling, inflammasome activation, metabolic flexibility, senescence, and nutritional modulation. In the proposed model, Burn-ON represents a state of increased cellular demand in which mitochondrial adaptation, stress-response signaling, autophagic quality control, redox homeostasis, and metabolic flexibility remain sufficiently preserved to sustain function and allow recovery. With persistent or repetitive stress, these adaptive mechanisms may progressively lose reversibility, defining a potential tipping point toward Burn-OUT. Burn-OUT is characterized conceptually by impaired mitochondrial quality control, reduced energetic reserve, defective autophagic flux, persistent inflammatory signaling, redox imbalance, metabolic inflexibility, and loss of functional recovery, with senescence or regulated cell death representing possible downstream outcomes. Nutrition and lifestyle may modulate this continuum by influencing nutrient sensing, substrate load, mitochondrial metabolism, autophagy, and inflammatory pathways. The Burn-ON/Burn-OUT model frames cellular stress as a double-edged biological process, in which adaptation and dysfunction represent different positions along a dynamic continuum. Longitudinal studies are needed to determine whether recovery kinetics and multidimensional biomarker profiles can distinguish these proposed states.

17 March 2026
Verified
Book Chapter
Open access
PDF file
LSLuiza Spiru
Luiza Spiru
Dominik ThorDominik Thor
Dominik Thor
MMMircea-Dan Marzan
Mircea-Dan Marzan
Alzheimer’s disease (AD) represents one of the most complex and pressing challenges of modern medicine, particularly in the context of global population aging. Despite major advances in molecular biology, neuroimaging, and digital health, Alzheimer’s disease remains largely diagnosed at a symptomatic stage, when neurodegeneration is already advanced and therapeutic options are limited. Recent large-scale population studies using blood-based biomarkers reveal that biological Alzheimer’s disease pathology is far more prevalent than clinically diagnosed dementia, highlighting a long and actionable preclinical phase for prevention and early intervention. This chapter adopts a lifespan and longevity-medicine perspective, integrating classical pathophysiological mechanisms with emerging concepts in brain resilience, stress biology, intrinsic capacity, and preventive medicine. We review current and emerging diagnostic tools – including fluid, imaging, digital, and AI-supported biomarkers – key mechanisms of disease pathogenesis, and multimodal therapeutic strategies. Particular emphasis is placed on the transition from symptom-based diagnosis to biology-based staging, early intervention, and personalized, adaptive care pathways. We address the “digital health paradox,” emphasizing that effective deployment of digital biomarkers requires objective assessment of digital competence rather than reliance on patient self-report, given documented discrepancies in older populations. Finally, we propose a Seniors-Oriented Technology Acceptance Model (STAM) and co-creation strategies to support age-inclusive, ethically governed, and scalable clinical implementation. Together, these approaches aim to preserve brain healthspan, delay disease progression, and translate geroscience principles into routine clinical practice.

12 November 2026 in Medical Sciences
Verified
Journal Article
Open access
PDF file
ACAlexandra Oana Constantin
Alexandra Oana Constantin
LBLiviu Bilteanu
Liviu Bilteanu
MMMircea Dan Marzan
Mircea Dan Marzan
DMDaniela Manuc
Daniela Manuc
RPRadu Cristian Popa
Radu Cristian Popa
LSLuiza Spiru
Luiza Spiru
Background/Objectives: Hospitalization frequently exacerbates muscle wasting and functional decline in vulnerable older adults, yet comprehensive geriatric assessments are often too time-consuming. This study evaluated the clinical utility of baseline and longitudinal bilateral handgrip strength (HGS), measured via a Squegg® digital dynamometer, as a rapid bedside marker of frailty and functional trajectory in hospitalized older adults. Methods: This retrospective cohort study included 131 older adults (mean age 74.9 ± 9.7 years, 75.6% female) admitted to an acute geriatric unit. Bilateral HGS was measured at admission and discharge using the Squegg® digital dynamometer. Participants were also evaluated using the Edmonton Frail Scale (EFS) for frailty, the Timed Up and Go (TUG) test for functional mobility, and the Mini-Mental State Examination (MMSE) for cognitive performance. Results: Bilateral mean HGS improved significantly from admission (18.5 ± 8.7 kg) to discharge (20.7 ± 9.1 kg), representing a mean within-participant increase of 2.16 ± 2.94 kg (p < 0.001), with 77.9% of the cohort exhibiting a positive trajectory. Admission HGS was strongly and inversely correlated with baseline EFS scores and TUG. In multivariable linear regression, higher EFS scores were associated with lower baseline HGS after adjustment for the included covariates. Exploratory models provided no statistically significant evidence of an association between baseline HGS or longitudinal HGS change and length of hospital stay (mean: 11.9 ± 1.8 days). Conclusions: Bedside digital handgrip strength may provide a complementary marker of frailty and functional mobility in hospitalized older adults. Measurement reliability and screening accuracy were not assessed in this study.